Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

Group 1 - Titan Pharmaceuticals, Inc. has successfully completed its merger with Black Titan Corporation and TalenTec Sdn. Bhd., with the combined company's shares trading on Nasdaq under the ticker symbol NASDAQ: BTTC [1][3] - Titan has become a wholly owned subsidiary of Black Titan Corporation effective October 1, 2025, as per the Merger and Contribution and Share Exchange Agreement dated August 19, 2024 [2] - Each share of Titan common stock was converted into ordinary shares of Black Titan on a one-for-one basis, and trading of Titan's common stock ceased on October 1, 2025 [3] Group 2 - Chay W. J., CEO of Black Titan, stated that the merger signifies a new chapter of innovation and global expansion, positioning the company to execute its strategic vision and deliver value to stakeholders [4] - ARC Group Ltd. served as the exclusive financial advisor to Black Titan Corporation for this transaction [4]